InvestSMART

Invex Therapeutics Ltd (ASX: IXC) - Announcements

Current share price for IXC : $0.110 0.005 (4.76%)+

ASX company news and announcements for Invex Therapeutics Ltd (IXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Invex Therapeutics Ltd (IXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Invex Therapeutics Ltd (IXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Invex Therapeutics Ltd (IXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8 Change in substantial holding 28 Nov 2023 8:16AM $0.230 $0.110 fallen by 52.17%
$8 Change of Director's Interest Notice x 3 27 Nov 2023 8:08PM $0.230 $0.110 fallen by 52.17%
$8 Notification of cessation of securities - IXC 22 Nov 2023 1:08PM $0.235 $0.110 fallen by 53.19%
$8 Invex Granted European Patent for Exenatide in Hydrocephalus 22 Nov 2023 8:14AM $0.235 $0.110 fallen by 53.19%
$8 Notification of cessation of securities - IXC 20 Nov 2023 8:18AM $0.230 $0.110 fallen by 52.17%
$8 Notification of cessation of securities - IXC 10 Nov 2023 12:53PM $0.225 $0.110 fallen by 51.11%
$8 Notification of cessation of securities - IXC 10 Nov 2023 11:20AM $0.235 $0.110 fallen by 53.19%
$8 Initial Director's Interest Notice 9 Nov 2023 12:03PM $0.230 $0.110 fallen by 52.17%
$8 Appointment of Non-executive Director 8 Nov 2023 4:31PM $0.230 $0.110 fallen by 52.17%
$8 Change in substantial holding 8 Nov 2023 11:26AM $0.225 $0.110 fallen by 51.11%
$8 Notice of General Meeting/Proxy Form 2 Nov 2023 3:57PM $0.215 $0.110 fallen by 48.84%
$8 Return of Capital - IXC 1 Nov 2023 3:20PM $0.195 $0.110 fallen by 43.59%
$8 Proposed Capital Return to Shareholders of $14.0 Million 1 Nov 2023 3:20PM $0.195 $0.110 fallen by 43.59%
$8 Notification of cessation of securities - IXC 20 Oct 2023 10:30AM $0.190 $0.110 fallen by 42.11%
$8 Notice of Annual General Meeting/Proxy Form 19 Oct 2023 3:10PM $0.190 $0.110 fallen by 42.11%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 12 Oct 2023 3:54PM $0.190 $0.110 fallen by 42.11%
$8 Change in substantial holding 28 Sep 2023 12:43PM $0.185 $0.110 fallen by 40.54%
$8 Date of AGM and Closing Date for Director Nominations 25 Sep 2023 4:14PM $0.200 $0.110 fallen by 45%
$8 Becoming a substantial holder 31 Aug 2023 2:42PM $0.205 $0.110 fallen by 46.34%
$8 Change of Director's Interest Notice 25 Aug 2023 9:20AM $0.180 $0.110 fallen by 38.89%
$8 Invex issued US patent for Traumatic Brain Injury 23 Aug 2023 11:58AM $0.185 $0.110 fallen by 40.54%
$8 Invex to close IIH Evolve Phase III Clinical Trial 21 Aug 2023 9:23AM $0.180 $0.110 fallen by 38.89%
$8 Trading Halt 18 Aug 2023 9:27AM $0.180 $0.110 fallen by 38.89%
$8 Corporate Governance Statement 2023 17 Aug 2023 3:52PM $0.180 $0.110 fallen by 38.89%
$8 Appendix 4G 17 Aug 2023 3:50PM $0.180 $0.110 fallen by 38.89%

76 - 100 of 300 results

Page 4 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.